Bid date, 2021-06-22
Auction date2021-06-22
Settlement date2021-06-23
Maturity Date2021-06-30
Nominal amount490 billion SEK
Interest rate, %0.00
Bid times09.30-10.00 (CET/CEST) on the Bid date
Confirmation of bids to
The lowest accepted bid volume1 million SEK
The highest accepted bid volume490 billion SEK
Allocation Time10.15 (CET/CEST) on the Bid date
Projected minimum liquidity surplus during the term979 billion SEK
Expected excess liquidity at full allotment489 billion SEK

Stockholm, 2021-06-22

To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire

One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

SBM Offshore announces share repurchase5.8.2021 07:05:00 CEST | Press release

August 5, 2021 SBM Offshore is pleased to announce a EUR150 million (c. US$180 million) share repurchase program, effective from August 5, 2021. The objective of the program is to reduce share capital and, in addition, to provide shares for regular management and employee share programs. The repurchase program is expected to be completed within the year 2021, and it will be accomplished under the authorization granted by the Annual General Meeting of the Company on April 7, 2021. The execution of the share repurchase program will be done under the terms of an engagement letter with a third party, performed in compliance with the safe harbor provisions for share repurchases, and therefore transactions may be carried out during closed periods. In accordance with the European Market Abuse Regulation, the Company will inform the market of the progress made in the execution of this program through weekly press releases and updates on its website. In accordance with normal practice to cater

KBC Group: Second-quarter result of 793 million euros5.8.2021 07:00:00 CEST | Press release

Press Release Outside trading hours - Regulated information* Brussels, 5 August 2021 (07.00 a.m. CEST) KBC Group: Second-quarter result of 793 million euros In many countries, the large-scale rollout of vaccines that started in the first quarter of 2021 is now running at full speed. While caution is still paramount, the general feeling is one of anticipation for a long-awaited, full resumption of social activities, and optimism for a worldwide economic recovery. From the start of this crisis almost a year and a half ago, we have taken responsibility in safeguarding the health of our staff and customers, while ensuring that services continue to be provided. We have also worked closely with government agencies to support all customers impacted by the coronavirus, implementing various measures such as loan deferrals. Besides the turmoil caused by the coronavirus crisis, various areas in Europe have been hit by recent extreme weather conditions. Parts of the Czech Republic were hit by a to

ObsEva Announces Second Quarter 2021 Financial Results and Business Update5.8.2021 07:00:00 CEST | Press release

-Linzagolix (Yselty®) for uterine fibroids: US New Drug Application filing planned in Q3:21; European marketing approval recommendation anticipated in Q4:21- -Linzagolix for endometriosis: Readout from Phase 3 EDELWEISS 3 study expected in Q4:21- -Ebopiprant: Global License Agreement completed with Organon- -Actively pursuing new indications and partnerships to maximize value of pipeline candidates- Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland– August 5, 2021 – ObsEva SA (NASDAQ: OBSV)(SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today reported financial results for the quarter ended June 30, 2021 and provided a business update. “The outset of 2021 was focused on strengthening the financial position of the company, and we have continued to execute on our strategic plan, which most recently includes the global license to Organon of development, manufacturing and

SBM Offshore Half Year 2021 Earnings5.8.2021 07:00:00 CEST | Press release

August 5, 2021 Record-breaking backlog, increased shareholder returns, positioning for New Energy Highlights Financial results in line with management expectationsRecord-level US$29.5 billion proforma backlog, up by c. US$8 billion Launch of EUR150 million (c. US$180 million) share repurchase programScaling-up renewables: 200 MW floating offshore wind development2021 Directional1 revenue guidance maintained at around US$2.6 billion2021 Directional EBITDA guidance maintained at around US$900 million The 2021 Half Year Results and Interim Financial Statements are published on the Company’s website under Bruno Chabas, CEO of SBM Offshore, commented: “All our three value platforms, Ocean Infrastructure, Growing the Core and New Energies show good performance in line with our vision and commitment for providing safe, sustainable and affordable energy. Our staff and contractor te

Hexagon Ragasco, the world’s leading manufacturer of composite LPG cylinders awarded Environmental Product Declaration5.8.2021 07:00:00 CEST | Press release

Hexagon Ragasco, a Hexagon company and world leading manufacturer of LPG composite cylinders – was awarded an Environmental Product Declaration (EPD) from EPD-Norway for the production of its cylinders. Hexagon Ragasco’s cylinders are produced at the company’s fully automated manufacturing plant in Raufoss, Norway. In the past 21 years, Hexagon Ragasco has sold over 19 million cylinders in over 85 countries. Value of an Environmental Product Declaration (EPD) An EPD discloses a product’s life cycle environmental impact and helps users to identify sustainable products. Both the underlying Life-Cycle Assessment (LCA) and the EPD are based upon international standards. Furthermore, it contains quantified information that enables comparison between products from the same product category and declares its environmental footprint towards predetermined environmental factors; one being the product’s carbon footprint. Hexagon Ragasco’s first EPD relates to the production phase of the LCA. In ad

Boyden Welcomes Healthcare & Life Sciences Expert Stephen Irish as Managing Partner, Japan4.8.2021 20:00:00 CEST | Press release

Long-term specialist in senior-level recruitment in Japan and Asia/Pacific joins Boyden as head of the Japan office and member of Boyden’s global healthcare & life sciences practice TOKYO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Boyden, a premier leadership and talent advisory firm with more than 75 offices in over 45 countries, is delighted to welcome Stephen Irish as Managing Partner and head of Boyden Japan. Based in Tokyo, Irish joins Boyden’s global healthcare & life sciences practice, leading senior level searches for clients in Japan and Asia/Pacific, as well as those headquartered outside the region. “Japan is a unique market, and requires specialist knowledge and understanding of the cultural nuances at the individual, organisational and government level,” commented Stephen Irish, Managing Partner, Boyden Japan. “Having worked with Japanese companies throughout my career, I am delighted to bring this experience into a collaborative, international environment with Boyden. For clients

Novo Nordisk's net profit increased by 10% in the first six months of 20214.8.2021 16:41:41 CEST | Press release

4 August 2021 - Financial report for the period 1 January 2021 to 30 June 2021 Operating profit decreased by 1% in Danish kroner and increased by 9% at constant exchange rates (CER).Sales increased by 5% in Danish kroner and by 12% at CER to DKK 66.8 billion. Sales in International Operations increased by 7% in Danish kroner (13% at CER), and sales in North America Operations increased by 1% in Danish kroner (11% at CER).Sales within Diabetes and Obesity care increased by 5% in Danish kroner to DKK 56.9 billion (13% at CER), driven by GLP-1 growth of 21% in Danish kroner (30% at CER) reflecting the uptake of Ozempic® and Rybelsus®. Obesity care grew by 23% in Danish kroner (34% at CER) and Biopharm sales remained unchanged in Danish kroner (increased by 7% at CER).In June 2021, Wegovy™, semaglutide 2.4 mg, was made available to patients in the US following the approval from the US Food and Drug Administration (FDA) for weight management in adults living with obesity.For the 2021 outloo